Portal de Periódicos da CAPES

Vincristine, prednisone, and daunomycin in acute leukemia of childhood.Writing committee

1971; Wiley; Volume: 27; Issue: 3 Linguagem: Inglês

10.1002/1097-0142(197103)27

1097-0142

Teresa J. Vietti, Kenneth A. Starling, Jordan R. Wilbur, Derrick Lonsdale, Daniel M. Lane,

Cancer Treatment and Pharmacology

CancerVolume 27, Issue 3 p. 602-607 ArticleFree Access Vincristine, prednisone, and daunomycin in acute leukemia of childhood. Writing committee Teresa J. Vietti MD, Corresponding Author Teresa J. Vietti MD Chairman Department of Pediatrics, Washington University School of Medicine, St. Louis, Mo.Headquarters, Southwest Cancer Chemotherapy Study Group, 6723 Bertner Drive Houston, Tex. 77025===Search for more papers by this authorKenneth Starling MD, Kenneth Starling MD Research Hematology, Texas Children's Hospital, Texas Medical Center, Houston, Tex.Search for more papers by this authorJ. R. Wilbur MD, J. R. Wilbur MD Department of Pediatrics, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston, Tex.Search for more papers by this authorDerrick Lonsdale MD, Derrick Lonsdale MD Department of Pediatrics, Cleveland Clinic, Cleveland, OhioSearch for more papers by this authorDaniel M. Lane MD, Daniel M. Lane MD The University of Oklahoma Medical Center, Children's Memorial Hospital, Oklahoma City, OklaSearch for more papers by this author Teresa J. Vietti MD, Corresponding Author Teresa J. Vietti MD Chairman Department of Pediatrics, Washington University School of Medicine, St. Louis, Mo.Headquarters, Southwest Cancer Chemotherapy Study Group, 6723 Bertner Drive Houston, Tex. 77025===Search for more papers by this authorKenneth Starling MD, Kenneth Starling MD Research Hematology, Texas Children's Hospital, Texas Medical Center, Houston, Tex.Search for more papers by this authorJ. R. Wilbur MD, J. R. Wilbur MD Department of Pediatrics, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston, Tex.Search for more papers by this authorDerrick Lonsdale MD, Derrick Lonsdale MD Department of Pediatrics, Cleveland Clinic, Cleveland, OhioSearch for more papers by this authorDaniel M. Lane MD, Daniel M. Lane MD The University of Oklahoma Medical Center, Children's Memorial Hospital, Oklahoma City, OklaSearch for more papers by this author First published: March 1971 https://doi.org/10.1002/1097-0142(197103)27:3 3.0.CO;2-5Citations: 19AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Two different regimens utilizing daunomycin, vincristine sulfate, and prednisone were administered in combination to treat 64 children with acute leukemia in relapse. All patients had received previous therapy with vincristine, prednisone, and/or daunomycin but none had received the 3 drugs in combination. Seven were known to be resistant to both vincristine and prednisone. The triple combination was effective in inducing remission in 44 of the children, but myelosuppression was severe and the results obtained were not significantly better than the much less toxic combination of vincristine and prednisone. References 1 Boiron, M., Jacquillat, C., Weil, M., Tanzer, J., Levy, D., Sultan, C., and Bernard, J.: Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet 1: 330–333, 1969. 10.1016/S0140-6736(69)91296-3 CASPubMedWeb of Science®Google Scholar 2 Bonadonna, G., and Monfardini, S.: Cardiac toxicity of daunorubicin (Letter). Lancet 1: 837, 1969. 10.1016/S0140-6736(69)92093-5 CASPubMedWeb of Science®Google Scholar 3 Calendi, E., Di Marco, A., Reggiani, M., Scarpinato, B., and Valentini, L.: On physiochemical interaction between daunomycin and nucleic acids. Biochim. Biophys. Acta 103: 25–49, 1965. 10.1016/0005-2787(65)90539-3 CASPubMedWeb of Science®Google Scholar 4 Di Marco, A.: Daunomycin pharmacological activity at the cellular level. Path. Biol. 15: 897–902, 1967. CASPubMedWeb of Science®Google Scholar 5 Di Marco, A., Gaetani, M., Dorigotti, L., Soldati, M., and Bellini, O.: Daunomycin: a new antibiotic with antitumor activity. Cancer Chemother. Rep. 38: 31–38, 1964. CASPubMedGoogle Scholar 6 Hewlett, J. S., Battle, J. D., Jr., Bishop, R. C., Fowler, W. M., Schwartz, S. O., Hagen, P. S., and Louis, J.: Phase II study of A-8103 (NSC-25154) in acute leukemia in adults. Cancer Chemother. Rep. 42: 25–28, 1964. CASPubMedGoogle Scholar 7 Holton, C. P.: Remission induction of childhood leukemia with daunomycin, vincristine and prednisone. Proc. Amer. Ass. Cancer Res. 10: 40, 1969. Web of Science®Google Scholar 8 Holton, C. P., Lonsdale, D., Nora, A. H., Thurman, W. G., and Vietti, T. J.: Clinical study of daunomycin (NSC-82151) in children with acute leukemia. Cancer 22: 1014–17, 1968. 10.1002/1097-0142(196811)22:5 3.0.CO;2-F CASPubMedWeb of Science®Google Scholar 9 Holton, C. P., Vietti, T. J., Nora, A. H., Donaldson, M. H., Stuckey, W. J., Jr., Watkins, W. L., and Lane, D. M.: Clinical study of daunomycin and prednisone for induction of remission in children with advanced leukemia. New Eng. J. Med. 280: 171–174, 1969. 10.1056/NEJM196901232800401 CASPubMedGoogle Scholar 10 Howard, J. P., and Tan, C.: Combined daunomycin-prednisone inductions in acute leukemia. Proc. Amer. Ass. Cancer Res. 8: 32, 1967. Google Scholar 11 Jacquillat, C., Najean, Y., Weil, M., Tanzer, J., Boiron, M., and Bernard, J.: Traitement des leucémies aiguës lymphoblastiques par la rubidomycine. Path. Biol. 15: 914–17, 1967. Google Scholar 12 Jacquillat, C., Weil, M., Boiron, M., and Bernard, J.: Traitement des leucémies aiguës par la rubidomycine. Un. Med. Canada 97: 8–12, 1968. CASPubMedGoogle Scholar 13 Jones, B.: Daunomycin in the treatment of resistant acute lymphoblastic leukemia. Blood 30: 890–91, 1967. Web of Science®Google Scholar 14 Lane, D. M., Haggard, M. E., Lonsdale, D., Starling, K., and Sullivan, M. P.: Remission induction in childhood leukemia with second course vincristine (NSC-67574) and prednisone (NSC-10023) therapy. Cancer Chemother. Rep. 54: 113–118, 1970. PubMedGoogle Scholar 15 Macrez, C., Marneffe-Lebrequier, H., Ripault, J., Clauvel, J. P., Jacquillat, C., and Weil, M.: Accidents cardiaques observés au cours des traitements par la rubidomycine. Path. Biol. 15: 949–953, 1967. CASPubMedWeb of Science®Google Scholar 16 Malpas, J. S., and Scott, R. B.: Daunorubicin in acute myelocytic leukemia (Letter). Lancet 1: 469–70, 1969. 10.1016/S0140-6736(69)91516-5 CASPubMedWeb of Science®Google Scholar 17 Marmont, A. M., Damasio, E., and Rossi, F.: Cardiac toxicity of daunorubicin. Lancet 1: 837–38, 1969. CASPubMedWeb of Science®Google Scholar 18 Masera, G., and Carnelli, V.: Terapia della leucemia acuta dell'infanzia con la nuova associazione daunomicina-vincristina-prednisone. Minerva Pediat. 21: 39–46, 1969. CASPubMedGoogle Scholar 19 Mathé, G., et al.: Haute frequence et qualite des remissions de la leucémie aiguë lymphoblastique chez l'enfant. Arch. Franc. Ped. 25: 181–188, 1968. PubMedWeb of Science®Google Scholar 20 Mathé, G., et al.: Acute lymphoblastic leukaemia treated with a combination of prednisone, vincristine, and rubidomycin. Lancet 2: 380–82, 1967. 10.1016/S0140-6736(67)92004-1 CASPubMedWeb of Science®Google Scholar 21 Shore, N. A., and Hartmann, J. R.: Preliminary evaluation of daunomycin in children with acute leukemia. Path. Biol. 15: 939, 1967. CASPubMedGoogle Scholar 22 Southwest Cancer Chemotherapy Study Group. Unpublished data. Google Scholar 23 Starling, K. A., Lane, D. M., Sutow, W. W., Monto, R. W., and Thurman, W. G.: Vincristine and prednisone remission induction in children with acute leukemia. To be published. Google Scholar 24 Tan, C., Tasaka, H., Yu, K. P., Murphy, M. L., and Karnofsky, D. A.: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Cancer 20: 333–53, 1967. 10.1002/1097-0142(1967)20:3 3.0.CO;2-K CASPubMedWeb of Science®Google Scholar Citing Literature Volume27, Issue3March 1971Pages 602-607 ReferencesRelatedInformation